{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:14:14Z","timestamp":1792239254224,"version":"4.4.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with relapsed\/refractory (RR) classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma, and follicular lymphoma. We report the results in cases of cHL. Adult patients with RR cHL who had received \u22651 prior lines of therapy and were ineligible for transplantation were treated in a dose-escalation cohort with 2 dose levels (DLs) and then on an expansion cohort at the recommended phase 2 dose (RP2D) in 21-day cycles. Vorinostat 100 mg twice a day (DL1) and 200 mg twice a day (DL2) was administered orally from days 1 to 5 and 8 to 12; all patients received pembrolizumab 200 mg IV every 3 weeks. The primary end point was safety and determination of RP2D. In total, 32 patients with cHL were enrolled, including 30 at DL2 (RP2D); 78% had received prior anti\u2013programmed cell death 1 (anti\u2013PD-1) therapy, and 56% were PD-1 refractory. Grade \u22653 adverse events (AEs) included hypertension (9%), neutropenia (9%), hypophosphatemia (9%), thrombocytopenia (6%), and lymphopenia (6%). Immune-related AEs included grade 1 or 2 thyroiditis (13%), grade 1 rash (6%), and grade 3 esophagitis\/duodenitis (3%). The overall response rate (ORR) was 72% and complete response (CR) rate was 34%. Patients refractory to prior PD-1 blockade (n\u00a0= 18) had ORR and CR rates of 56% and 11%, respectively. Pembrolizumab and vorinostat was well tolerated with a high ORR rate in RR cHL including in anti\u2013PD-1\u2013refractory disease. This trial was registered at www.clinicaltrials.gov as #NCT03150329.<\/jats:p>","DOI":"10.1182\/blood.2023020485","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T22:03:06Z","timestamp":1687298586000},"page":"1359-1370","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"first","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-4288","authenticated-orcid":false,"given":"James","family":"Godfrey","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo","family":"Song","sequence":"additional","affiliation":[{"name":"3Department of Pathology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-1271","authenticated-orcid":false,"given":"Colt","family":"Egelston","sequence":"additional","affiliation":[{"name":"4Department of Immuno-Oncology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-5193","authenticated-orcid":false,"given":"Sandrine","family":"Puverel","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-8603","authenticated-orcid":false,"given":"Saro","family":"Armenian","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Nikolaenko","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nwangwu","sequence":"additional","affiliation":[{"name":"4Department of Immuno-Oncology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-513X","authenticated-orcid":false,"given":"Weihua","family":"Guo","sequence":"additional","affiliation":[{"name":"4Department of Immuno-Oncology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[{"name":"6Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[{"name":"4Department of Immuno-Oncology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Daniels","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Kennedy","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacolle","family":"Peters","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rosen","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-2811","authenticated-orcid":false,"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"1Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2023101915210124200_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023101915210124200_bib2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023101915210124200_bib3","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"Gillessen","year":"2021","journal-title":"Lancet Haematol"},{"issue":"25","key":"2023101915210124200_bib4","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9323","key":"2023101915210124200_bib5","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"6","key":"2023101915210124200_bib6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for\u00a0survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2023101915210124200_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023101915210124200_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101915210124200_bib9","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/S2152-2650(21)01854-1","article-title":"Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL)","volume":"21","author":"Ansell","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2023101915210124200_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2021-147881","article-title":"Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL) [abstract]","volume":"138","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023101915210124200_bib11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2011-10-292003","article-title":"Histone\/protein deacetylases and T-cell immune responses","volume":"119","author":"Akimova","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2023101915210124200_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023101915210124200_bib13","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"27","key":"2023101915210124200_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023101915210124200_bib15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/biom10071061","article-title":"Epigenetic mechanisms of resistance to immune checkpoint inhibitors","volume":"10","author":"Perrier","year":"2020","journal-title":"Biomolecules"},{"key":"2023101915210124200_bib16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"2023101915210124200_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023101915210124200_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/1535-7163.MCT-18-1068","article-title":"HDAC3 inhibition upregulates PD-L1 expression in b-cell lymphomas and augments the efficacy of anti-PD-L1 therapy","volume":"18","author":"Deng","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2023101915210124200_bib19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2023101915210124200_bib20","doi-asserted-by":"crossref","first-page":"e001696","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"2023101915210124200_bib21","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"2023101915210124200_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2023101915210124200_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023101915210124200_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2019.1672052","article-title":"Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies","volume":"61","author":"Siddiqi","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023101915210124200_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A\u00a0phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023101915210124200_bib26","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","article-title":"Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome","volume":"10","author":"Werner","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"2023101915210124200_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023101915210124200_bib28","doi-asserted-by":"crossref","first-page":"e0124531","DOI":"10.1371\/journal.pone.0124531","article-title":"Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival","volume":"10","author":"Barros","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"2023101915210124200_bib29","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023101915210124200_bib30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2023101915210124200_bib31","first-page":"3827","article-title":"MGCD0103 induces apoptosis and simultaneously increases the expression of NF-\u03baB and PD-L1 in classical Hodgkin's lymphoma","volume":"16","author":"Huang","year":"2018","journal-title":"Exp Ther Med"},{"issue":"1","key":"2023101915210124200_bib32","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3324\/haematol.2018.196279","article-title":"Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment","volume":"104","author":"Sasse","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2023101915210124200_bib33","doi-asserted-by":"crossref","first-page":"e0204870","DOI":"10.1371\/journal.pone.0204870","article-title":"Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma","volume":"13","author":"Hollander","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"2023101915210124200_bib34","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines","volume":"112","author":"Buglio","year":"2008","journal-title":"Blood"},{"issue":"32","key":"2023101915210124200_bib35","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2023101915210124200_bib36","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but\u00a0no cytotoxic T-cell activation in classic\u00a0Hodgkin lymphoma treated with\u00a0anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023101915210124200_bib37","doi-asserted-by":"crossref","first-page":"e13804","DOI":"10.1097\/MD.0000000000013804","article-title":"Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report","volume":"98","author":"Lepir","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"2023101915210124200_bib38","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2012-06-439570","article-title":"Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma","volume":"120","author":"Steidl","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/16\/1359\/2084480\/blood_bld-2023-020485-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/16\/1359\/2084480\/blood_bld-2023-020485-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T15:22:11Z","timestamp":1697728931000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/16\/1359\/496475\/Pembrolizumab-plus-vorinostat-induces-responses-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,10,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020485","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}